Description
Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice
Article: Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice
€3.03
€3.03
Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice
Top
Notifications
